{"id":"hydrocodone-er","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dependence/addiction risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocodone is a semi-synthetic opioid that acts as an agonist at mu-opioid receptors throughout the brain and spinal cord. By binding to these receptors, it modulates pain signal transmission and produces analgesic effects. The extended-release formulation is designed to provide sustained pain relief over an extended dosing interval.","oneSentence":"Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system to reduce pain perception and provide analgesia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:05.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain requiring continuous opioid therapy"}]},"trialDetails":[{"nctId":"NCT02222740","phase":"PHASE2","title":"A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2002-09","conditions":"Osteoarthrosis","enrollment":37},{"nctId":"NCT02117141","phase":"PHASE1","title":"To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2002-06","conditions":"Healthy","enrollment":12},{"nctId":"NCT02197156","phase":"PHASE2","title":"A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2002-08","conditions":"Postoperative Pain","enrollment":241},{"nctId":"NCT02244762","phase":"PHASE1","title":"Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2011-02","conditions":"Renal Impairment","enrollment":37},{"nctId":"NCT02242734","phase":"PHASE1","title":"Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2011-02","conditions":"Hepatic Impairment","enrollment":30},{"nctId":"NCT02126917","phase":"PHASE1","title":"A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2009-11","conditions":"Healthy","enrollment":30},{"nctId":"NCT01922739","phase":"PHASE3","title":"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Low Back Pain","enrollment":182},{"nctId":"NCT01400139","phase":"PHASE3","title":"Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-07","conditions":"Chronic Nonmalignant and Nonneuropathic Pain","enrollment":922},{"nctId":"NCT01452529","phase":"PHASE3","title":"Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-10","conditions":"Chronic Low Back Pain","enrollment":905},{"nctId":"NCT03642873","phase":"PHASE1","title":"Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate","status":"COMPLETED","sponsor":"Reckitt Benckiser LLC","startDate":"2007-05-05","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT01631513","phase":"PHASE4","title":"An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)","status":"WITHDRAWN","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-08","conditions":"Pain, Chronic Back Pain, Chronic Low Back Pain","enrollment":""},{"nctId":"NCT01789970","phase":"PHASE3","title":"Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-03","conditions":"Low Back Pain","enrollment":625},{"nctId":"NCT01223365","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-10","conditions":"Chronic Pain","enrollment":330},{"nctId":"NCT01240863","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-11","conditions":"Chronic Pain","enrollment":391},{"nctId":"NCT00314340","phase":"PHASE4","title":"A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-11","conditions":"Chronic Pain","enrollment":12},{"nctId":"NCT02542098","phase":"PHASE2","title":"Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children","status":"WITHDRAWN","sponsor":"Purdue Pharma LP","startDate":"2017-01","conditions":"Pain","enrollment":""},{"nctId":"NCT02897414","phase":"","title":"ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases","status":"UNKNOWN","sponsor":"ER/LA Opioid REMS Program Companies (RPC)","startDate":"","conditions":"Opioid-related Disorders, Opioid Addiction, Narcotic Abuse","enrollment":13015}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BLOOD POTASSIUM INCREASED"},{"count":1,"reaction":"BODY TEMPERATURE INCREASED"},{"count":1,"reaction":"BURNING SENSATION"},{"count":1,"reaction":"CARDIAC ARREST"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":1,"reaction":"DEPENDENCE"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"LYMPHADENOPATHY"}],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CEP-33237","Hydrocodone bitartrate extended-release tablets","Hydrocodone bitartrate extended-release"],"phase":"phase_3","status":"active","brandName":"Hydrocodone ER","genericName":"Hydrocodone ER","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system to reduce pain perception and provide analgesia. Used for Moderate to severe chronic pain requiring continuous opioid therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}